136 related articles for article (PubMed ID: 8732471)
1. Menorest: technical development and pharmacokinetic profile.
Marty JP
Eur J Obstet Gynecol Reprod Biol; 1996 Apr; 64 Suppl():S29-33. PubMed ID: 8732471
[TBL] [Abstract][Full Text] [Related]
2. New trends in transdermal technologies: development of the skin patch, Menorest.
Marty JP
Int J Gynaecol Obstet; 1996 Mar; 52 Suppl 1():S17-20. PubMed ID: 8666122
[TBL] [Abstract][Full Text] [Related]
3. 17Beta-estradiol delivered by three different matrix patches 50 microg/day: a three way cross-over study in 21 postmenopausal women.
Rohr UD; Nauert C; Stehle B
Maturitas; 1999 Sep; 33(1):45-58. PubMed ID: 10585173
[TBL] [Abstract][Full Text] [Related]
4. Comparative bioequivalence studies with Estradot and Menorest transdermal systems.
Hossain M; Quebe-Fehling E; Sergejew T; Schmidt G; Skerjanec A; Cohen A; Krinsky L; Ibarra de Palacios P
Maturitas; 2003 Nov; 46(3):187-98. PubMed ID: 14585521
[TBL] [Abstract][Full Text] [Related]
5. Plasma estradiol concentrations and pharmacokinetics following transdermal application of Menorest 50 or Systen (Evorel) 50.
Reginster JY; Albert A; Deroisy R; Colette J; Vrijens B; Blacker C; Brion N; Caulin F; Mayolle C; Regnard A; Scholler R; Franchimont P
Maturitas; 1997 Jun; 27(2):179-86. PubMed ID: 9255753
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of Menorest 50 compared with Estraderm TTS 50 in the treatment of postmenopausal symptoms. A randomized, multicenter, parallel group study.
Pornel B; Genazzani AR; Costes D; Dain MP; Lelann L; Vandepol C
Maturitas; 1995 Nov; 22(3):207-18. PubMed ID: 8746878
[TBL] [Abstract][Full Text] [Related]
7. Improved patient acceptability with a transdermal drug-in-adhesive oestradiol patch.
Lake Y; Pinnock S
Aust N Z J Obstet Gynaecol; 2000 Aug; 40(3):313-6. PubMed ID: 11065040
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the local tolerability and adhesion of a new matrix system (Menorest) for estradiol delivery with an established transdermal membrane system (Estraderm TTS).
Erianne JA; Winter L
Maturitas; 1997 Mar; 26(2):95-101. PubMed ID: 9089558
[TBL] [Abstract][Full Text] [Related]
9. Bioavailability of estradiol from two matrix transdermal delivery systems: Menorest and Climara.
Andersson TL; Stehle B; Davidsson B; Höglund P
Maturitas; 2000 Jan; 34(1):57-64. PubMed ID: 10687883
[TBL] [Abstract][Full Text] [Related]
10. Menorest: a clinical overview.
Wren B
Int J Gynaecol Obstet; 1996 Mar; 52 Suppl 1():S27-9. PubMed ID: 8666124
[TBL] [Abstract][Full Text] [Related]
11. Estradiol pharmacokinetics after transdermal application of patches to postmenopausal women: matrix versus reservoir patches.
Reginster JY; Donazzolo Y; Brion N; Lins R
Climacteric; 2000 Sep; 3(3):168-75. PubMed ID: 11910618
[TBL] [Abstract][Full Text] [Related]
12. Plasma profiles of transdermal 17 beta-estradiol delivered by two different matrix patches. A four-way cross-over study in postmenopausal women.
Rohr UD; Ehrly AM; Kuhl H
Arzneimittelforschung; 1997 Jun; 47(6):761-7. PubMed ID: 9239456
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of irritation and sensitisation of two 50 microg/day oestrogen patches.
Toole J; Silagy S; Maric A; Fath B; Quebe-Fehling E; Ibarra de Palacios P; Laurin L; Giguere M
Maturitas; 2002 Dec; 43(4):257-63. PubMed ID: 12468134
[TBL] [Abstract][Full Text] [Related]
14. Absorption and bioavailability of oestradiol from a gel, a patch and a tablet.
Järvinen A; Nykänen S; Paasiniemi L
Maturitas; 1999 Jun; 32(2):103-13. PubMed ID: 10465378
[TBL] [Abstract][Full Text] [Related]
15. Comparative bioavailability study of an once-a-week matrix versus a twice-a-week reservoir transdermal estradiol delivery systems in postmenopausal women.
Baracat E; Haidar M; Castelo A; Tufik S; de Lima GR; Vieira JG; Peloso U; Casoy J
Maturitas; 1996 Apr; 23(3):285-91. PubMed ID: 8794422
[TBL] [Abstract][Full Text] [Related]
16. Osteoporosis prevention clinical study program.
Delmas P; Gimona A
Eur J Obstet Gynecol Reprod Biol; 1996 Apr; 64 Suppl():S39-45. PubMed ID: 8732473
[TBL] [Abstract][Full Text] [Related]
17. Bioavailability Study of Menorest®, a New Estrogen Transdermal Delivery System, Compared with a Transdermal Reservoir System.
Le Roux Y; Borg ML; Sibille M; Thebault J; Renoux A; Douin MJ; Djebbar F; Dain MP
Clin Drug Investig; 1995 Sep; 10(3):172-8. PubMed ID: 27519201
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of percutaneous estradiol: a crossover study using a gel and a transdermal system in comparison with oral micronized estradiol.
Scott RT; Ross B; Anderson C; Archer DF
Obstet Gynecol; 1991 May; 77(5):758-64. PubMed ID: 2014092
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of estradiol and of estrone during repeated transdermal or oral administration of estradiol.
Setnikar I; Rovati LC; Vens-Cappell B; Hilgenstock C
Arzneimittelforschung; 1996 Aug; 46(8):766-73. PubMed ID: 9125276
[TBL] [Abstract][Full Text] [Related]
20. [Transdermal estradiol--the possibility for replacement therapy in the postmenopause].
Rachev E
Akush Ginekol (Sofiia); 1994; 33(3):45-7. PubMed ID: 7793531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]